When the Cure Complicates: Ifosfamide, Methylene Blue, and A Life-Threatening Dilemma

Ifosfamide, an alkylating agent and a cyclophosphamide analog, can be used alone or in combination with other agents as salvage therapy for metastatic soft tissue sarcoma. Neurotoxicity, often presenting as encephalopathy, is a common side effect of ifosfamide therapy, affecting up to 60% of patients.1 Symptoms can range in severity from mild cognitive disturbances to severe, potentially fatal neurological impairments, such as hallucinations, confusion, drowsiness, and coma, which may develop within 2 to 96 hours of drug administration.2 Treatment of neurotoxicity includes cessation of ifosfamide and initiation of methylene blue (MB), which is used as both a therapeutic and prophylactic agent in the management of ifosfamide-induced encephalopathy (IFE). It works by inhibiting monoamine oxidase (MAO), thereby preventing the accumulation of the neurotoxic metabolite chloroacetaldehyde.3 MB is known to increase the risk of serotonin syndrome (SS) when used alongside serotonergic medications due to its MAO inhibition, which leads to the buildup of 5-hydroxytryptamine (5-HT), potentiating SS.4 Treatment of SS includes discontinuing all serotonergic agents and administration of cyproheptadine, a serotonin 5-HT2 receptor antagonist and histamine H1 receptor antagonist. This report describes a patient on serotonergic agents who presented with rapidly progressing sarcoma, where the decision was made to initiate salvage ifosfamide therapy, highlighting the complex decisionmaking involved in managing such cases. While ifosfamide offers a potential option to extend survival, its use is associated with significant challenges, particularly due to the risk of neurotoxicity. In this case, the patient being on serotonergic agents complicates matters further, as ifosfamide neurotoxicity may necessitate the use of MB, a known monoamine oxidase inhibitor that can trigger serotonin syndrome. The interplay of these factors requires careful consideration, balancing the benefits of ifosfamide with the risk of life-threatening complications